The EpigenCare offering is now closed and is no longer accepting investments.


Blockchain-based Skincare Platform

Regulation Crowdfunding
Farmingdale, NY
Accepting International Investment
Play video

Truly Personalized Skincare.

An At-Home Epigenetic Test

The age old question when it comes to skincare routines: "Is this skincare product really working for me?" The world spends $130 billion on skincare annually -- with everyone's skin being individually unique, there is a constant search for the ideal product that truly works.

At EpigenCare, we're connecting consumers with the best skincare products through a direct-to-consumer personal epigenomics test. Our matching engine’s algorithm filters through thousands of products from skincare companies based on the ingredients' epigenetic effects on one's skin profile, to deliver scientifically targeted and actionable solutions in the analysis test report.

Data Privacy Enforced by Blockchain

EpigenCare is transforming the skincare industry by strategically commoditizing skin profiles in a way that directly benefits the consumer. Our platform will have continuously updated consumer skin profiles through our personal epigenomics test, so that skincare companies can target scientifically matched products to them.

The major concern of consumers using DNA-based tests is absolute privacy; how does one know what a company does with the data? In our model, companies must operate within our defined scope of the ecosystem to match skincare products to consumer epigenetic profiles. Companies never access actual data or identifiable info. Data is anonymized and recorded on the blockchain ledger to create data provenance, allowing consumers to verify that their data is used solely for their own benefit without revealing identifiable information.

The Offering

InvestmentEquity Option and Revenue Sharing Rights digital instrument, designated as "EPIC Tokens"

$0.40 per EPIC security token | 2,675,000* available for sale through this offering

50,000,000 security tokens total from all offerings, 60,000,000 security tokens total fixed supply

Equity Conversion Rights

1 EPIC = 0.2 Shares of Common Stock

Option to Convert Minimum of 5 EPIC to 1 Share of Common Stock

48,000,000 Common Stock shares currently outstanding out of 80,000,000 authorized

Revenue Sharing Rights

Unconverted EPIC holders receive revenue sharing payments based on 15% and 10% of first 2 years of revenue, respectively, and 5% thereafter

Revenue sharing payments are paid based on fixed proportion of 60,000,000 EPIC

Revenue sharing is first paid at the end of the first year, then quarterly thereafter

*All perks and tokens will be delivered after the campaign is completed, and upon availability of the tokens.  See Offering Summary below for additional terms.

How Our Skincare Test Works

In December 2017, we've developed a direct-to-consumer personal epigenomics test to measure DNA methylation levels of a proprietary panel of genes that are responsible for key skin functions (e.g., aging, elasticity, moisture retention, etc.) in their current state. Our at-home kit collects DNA from skin (rather than saliva) through a non-invasive adhesive method which properly reflects skin quality changes after environmental interaction.

Genetics vs. Epigenetics

Epigenetics is the study of biological mechanisms (e.g., DNA methylation) that can switch genes on or off. Whereas you have the same genetics from the day you're born and throughout your entire life, epigenetics on the other hand encapsulates the dynamic and current state of your skin. This enables true monitoring of one's skincare regimen on a biological, gene function level. Learn more.

The Science Behind Our Test

Consumers will self-collect DNA from their skin with a non-invasive kit and mail it back to our facilities for methylation-based next-generation sequencing. Our test looks at a proprietary panel of epigenetic markers strongly associated with eight major skin quality indicators:

  • Aging
  • Firmness & Elasticity
  • Moisture
  • DNA Damage & Repair
  • Cell Regeneration
  • Sensitivity Response
  • Oxidation & Antioxidation
  • Pigmentation

We then look at hundreds of skincare product ingredients and their effects on these indicators. We then cross-reference the ideal ingredient composition with over 20,000 skincare products to develop match candidates that can be delivered as actionable product recommendations in the consumer's report.

Our panel of epigenetic markers was developed through the supporting effort of EpiGentek, a renowned supplier of epigenetic research reagents. These markers are well proven to be associated with the indicators in many academic publications as well as in our own lab research. For example, the SEC31L2 gene, whose protein product regulates collagen secretion, is highly methylated in the skin of older individuals.

Our Recurring Business Model

We're building a web platform that matches skincare products to consumer profiles generated by our test. Our matching engine will allow us to algorithmically match the optimal composition of existing products on the market to the consumer's epigenetic skin profile. Skincare companies can leverage the matching engine and target their products to epigenetically matched consumer epigenetic profiles. Because skin is dynamic and can be encapsulated through epigenetics, our test allows for a recurring business model by quantifying progress of one's skincare routine. Whenever a company's product is matched to the consumer, he or she is incentivized with loyalty points that can be spent to subsidize additional skincare tests. We recommend a test every six months to track progress.

A Match-and-Market Platform for Companies

Skincare companies can pay to access our matching engine and insert their products into a consumer’s epigenetic test report as follows:

  1. Completed skincare tests with available recommendation slot inventory are sent to a temporary holding pool for companies to have a chance to target profiles before the reports are delivered to the consumers; or
  2. Companies can select the data segments to reach or a specific product they want to promote, then set their budget and competitive bid price (guided by predictive modeling), which will enable their products to be auto-inserted into matched consumer’s reports as the tests come. 

After establishing a baseline requirement of scientific matching, we allow the company to further improve the match for the consumer by aligning the brand’s marketing position with the demographic. In other words, companies can further narrow down non-scientific segments such as age range, ethnicity, location, and even lifestyle factors such as weekly hours of sun exposure.

A Blockchain-Enforced, Structured Ecosystem

Unlike many blockchain based platforms, we are building a structured ecosystem rather than an open ecosystem. This allows us to address the major problem of perceived intrusiveness often associated with direct-to-consumer tests requiring DNA. In our controlled ecosystem, data segments can only be targeted by companies to deliver a personalized product to the consumer, and this can be proven to consumers on the immutable ledger feature of the blockchain. Companies must operate within the defined scope of the platform.

Whenever a purchase is made by companies or the consumer, special non-tradeable tokens (separate from EPIC) move seamlessly on the blockchain to create data provenance. When targeted by skincare companies with a product match, consumers are rewarded these special tokens that act as loyalty points and can be spent towards further tests. This tokenization allows for data to be associated with transaction hash IDs on the blockchain ledger. Thus consumers will be able to transparently verify that data is used strictly for their own benefit, while anonymizing their identities. Skincare companies never see the consumer’s actual data or personally identifiable information.

Investing in Our Equity Option Tokens

An investment into the valuable, core business mechanism of our company.

Equity Ownership - After 1 year, EPIC tokens have a conversion option for equity shares. 5 EPIC can be redeemed for 1 Common Stock of EpigenCare Inc., a United States C-Corporation. There are 48,000,000 shares currently outstanding out of 80,000,000 total authorized.

Revenue Sharing - All EPIC holders will receive 15% & 10% revenue distribution (payable as ETH) in the first two years of operation, respectively, after completion of this offering. Afterwards, EPIC holders will receive 5% quarterly of all revenue, including skincare test sales and product match sales.

Futureproofed - Because of our due diligence to structure our token as an SEC-defined security, we mitigate any unexpected impact from regulatory changes. As more exchanges become SEC compliant (e.g., registered Alternative Trading Systems), our tokens will be one of the few legally qualified to trade on them.

Market Opportunity

In 2016, global skincare industry revenue was $130 billion USD. By 2023, the industry is expected to grow 5% annually to over $180 billion[1]. According to a 2017 US survey, around 147 million US residents regularly purchased skincare products, 30 million of whom spent between $100 to $500 per person within 3 months (or $400 to $2,000 annually), with a further 1.4 million consumers spending more than $2,000 annually[2]. To calculate the estimated number of regular skincare product users globally, we need to account for purchasing power parity and thus we looked at the lowest spending tier in the US -- 75 million US residents spent less than $50 within 3 months (or less than $200 annually). If we take a median spend of $100 per person annually and apply it on a global basis, and since the global market value for skincare products is over $130 billion, then we can estimate that a total of at least 1 billion people regularly purchases skincare products.

Preference for Scientific Personalization

A recent study shows that 45% of adults are interested in a scientifically based test for personal skincare and would even prefer this compared to getting their product from other channels such as department store representatives or filling out online questionnaires[3]. With our personal epigenomics solution, if we are able to capture just 9.6% of the 1 billion users in the global skincare product market (a rate determined by applying the 45% science preference to the upper spending US proportion of 31.4 million out of 147 million consumers), then the number of personalized tests can reach over 96 million each year – a potential $20-30 billion market for skincare tests.

Source: Euromonitor International

[1] “Cosmetic Skin Care Market: Global Industry Analysis, Trends, Market Size & Forecasts to 2023.” Infinium Global Research, September 2017.

[2] “U.S. population: How much money did you spend on skin care products in the last 3 months?” Statista, September 2017.

[3] “Skin Care Made in the Lab Just for You: The Future of Personalization.” Canadean, 2014.

A Formula for Success

We will operate on the global market, with our initial target demographic as the high-spending segment in the United States. Our revenue forecast is as follows:

2018: $0.5 million; 2019: $5 million; 2020: >$20 million

To achieve $1 billion USD in annual revenue before the ten-year mark, we are aiming to capture 5% of the 30 million high spending US segment with 2 skincare tests per year. On a global scale, this revenue goal may be achieved much earlier and/or even higher.


  • Consumers spend $150-$300 per skincare test, with an average of $225 to factor in reward subsidies
  • Companies spend about $10 per targeted consumer via a bidding process for available recommendation slots in the test report

Revenue Calculations:

  • $675 million: Sell 2 tests at $225 each to 5% of 30 million users annually (30 million users x 5% x 2 tests x $225)
  • $360 million: Sell 12 targeted recommendation slots at $10 each per test profile annually (3 million tests x 12 slots x $10)

"This revolutionary business model promises to uniquely take advantage of the rapidly developing fields of epigenetics and blockchain to develop a database [and] solve the problem of product selection for personalized targeted skin care. It reduces the costs and frustrations of multiple product trials by consumers, provides cosmetic companies with another tool to guide product development, and provides a basis for monetization by the consumer participants and EpigenCare." -

Dr. Richard Wildnauer, Business Advisor, Former CEO of NeoStrata and VP at Johnson & Johnson

In the Press

EpigenCare Offers Personalized Skin Care via Epigenetics
February 21, 2018

The personalized skin care trend is moving forward with scientific options—EpigenCare hopes to enter this growing market by connecting skin care companies with consumers based on their epigenetic profile.

EpigenCare uses epigenetics, blockchain and artificial intelligence innovation
April 16, 2018

Winning the Johnson & Johnson Innovation Digital Beauty QuickFire Challenge for Skin Care competition emphasises the prevalence of epigenetics, blockchain, and artificial intelligence (AI) in skin care developments.

How Crypto-Economics is Redefining Telemedicine
January 1, 2018

One such example test is an in-house skin care examination that tailors skin care regiments to an individual’s unique biological makeup. The in-home, non-invasive epigenetic skin care test reveals the dynamic state of the person’s skin, enabling the personalization of skin care products...

EpigenCare Pioneers Personalized Skincare Based on Your Unique Epigenetic Signature
March 15, 2018

Pinpointing factors that make a person unique could shift the entire landscape of how we attend to our health – from exercise plans to custom diets and even skincare regimens. The concept of personalization has pierced the bubble of the prevailing “one size fits all” mentality, deflating the...

EpigenCare proposes a personalized skincare solution based on blockchain and epigenetics
February 24, 2018

Another company has decided to gain in on the crypto hype by announcing the launch of a blockchain based platform to revolutionize the skincare industry. EpigenCare uses epigenetic techniques and the blockchain technology to create personalized skincare products.

The world’s first project for truly personalized skin care based on epigenetics and blockchain technology
February 24, 2018

The world’s first project for truly personalized skin care based on epigenetics and blockchain technology has been announced by EpigenCare Inc. The project consists of a digital platform that will link consumers with skincare companies through a scientific matching algorithm based on the consumer’s

EpigenCare using epigenetics and blockchain technology to disrupt the skincare industry
February 27, 2018

Biotechnology company EpigenCare Inc. says it has created the world’s first project for truly personalized skincare based on epigenetics and blockchain technology. According to a media release, the digital platform will connect consumers with skincare companies using a scientific matching algo...

EpigenCare Offers Personalized Skin Care via Epigenetics
February 21, 2018

The personalized skin care trend is moving forward with scientific options—EpigenCare hopes to enter this growing market by connecting skin care companies with consumers based on their epigenetic profile. According to the company, 45% of adults are interested in a scientific test such as this for...

Block Chain-based Skin Care? Can anti-aging formulas get any more hyped?
February 21, 2018

How many buzzwords can fit in a headline? A startup company is relying on epigenetics and blockchain technology to power its customers' skin care formulas. Now all EpigenCare needs is Ivanka Trump to sign on as a spokesmodel. The Farmingdale, NY company says it has created the world's first...

EpigenCare Releases Epigenetics and Blockchain Technology for Personalized Skincare
March 4, 2018

The first skincare project in the world for personalized skincare has been launched. This project was revealed by EpigenCare and based on epigenetics and blockchain technology. Based in New York, EpigenCare is a personal epigenomics and digital biotechnology company that provides direct...

EpigenCare matches skin types with best product
February 22, 2018

Epigenomics and digital biotechnology company EpigenCare has revealed the world’s first project for personalised skincare based on epigenetic and blockchain technology. The biotechnology company’s digital platform will connect consumers with skincare companies using a scientific matching algo...

EpigenCare Offers Personalized Skin Care via Epigenetics
March 15, 2018

The personalized skin care trend is moving forward with scientific options—EpigenCare hopes to enter this growing market by connecting skin care companies with consumers based on their epigenetic profile. According to the company, 45% of adults are interested in a scientific test such as this for...

EpigenCare EPIC ICO: Biotech Personalized Skincare On Blockchain?
March 19, 2018

EpigenCare has been envisioned to be the first biotech company in the world to offer personalized skincare. It combines the blockchain and epigenetics. The developers of this project have been able to develop a personal epigenomics test. This test will be used to measure DNA methylation levels....

EpigenCare wins digital beauty award
April 10, 2018

EpigenCare, a US-based personalised skincare startup, has won Johnson & Johnson’s 2018 Digital Beauty Quickfire Challenge with a home testing kit that empowers consumers to make better skincare choices...

EpigenCare crowned Digital QuickFire Challenge for Skin Care winner
April 27, 2018

EpigenCare has been announced as one of two winners who snatched the top spot in Johnson & Johnson’s Digital QuickFire Challenge. The New York-based company will release its direct-to-consumer test later this year, which indicates the quality of users' skin, such as ageing, elasticity, moisture...

'EpigenCare' Uses At-Home Tests to Suggest Tailored Solutions
April 6, 2018

EpigenCare is a personalized skincare platform that uses an at-home test to develop "epigenetic profiles and skincare recommendations for the consumer." As part of Johnson & Johnson’s Digital QuickFire Challenge, EpigenCare was named one of the winners. EpigenCare's direct-to-consumer test kits...

EpigenCare: Personalized Skincare Products Using DNA Tests?
April 13, 2018

For most women, skincare involves trying dozens of products until they find one that works. While such an approach may ultimate enable one to find a viable formula, the process is tedious, tiring, expensive, and it may not even lead one to find a formula that is able to deliver the best potential...

April 27, 2018

If you’ve ever shopped for a skincare product to address a specific issue, such as acne or eczema, you’ve probably wondered: Will this work for me? Is this really the best product for my skin? Until you try it, there’s usually no way to know for sure. But two rising tech companies—EpigenCare...

Offering Summary

EpigenCare Inc.

Corporate Address
110 Bi County Blvd. Ste. 122
Farmingdale, NY 11735

Description of Business
Digital biotechnology company for epigenetic-based personalized skincare

Type of Security Offered
ERC20-Standard Digital Tokens

Name or Symbol of Security
EpigenCare Credits or "EPIC" Tokens
Purchase Price of Security Offered

Minimum Investment Amount (per investor) 

The Investment Offering

$0.40 per EPIC security token | 2,675,000* available for sale through this offering

*Maximum subject to adjustment for bonus tokens. See 10% Bonus below

50,000,000 security tokens total from all offerings, 60,000,000 security tokens total fixed supply

Option to Convert 5 EPIC to 1 Common Stock after 1 year

48,000,000 Common Stock currently outstanding out of 80,000,000 authorized

EPIC holders receive revenue sharing payments based on 15% and 10% of first 2 years of revenue, respectively, and 5% thereafter

Revenue sharing payments are paid based on fixed proportion of 60,000,000 EPIC

Revenue sharing is first paid at the end of a 1-year holding period, then quarterly thereafter


$400+ Acknowledgement of contribution on official EpigenCare webpage (optional)

$800+ 5% Additional Token Bonus

$2,400+ 10% Additional Token Bonus

$4,000+ 10% Additional Token Bonus + 1 Transferable First-Access Voucher for a Skincare Test ($299 value, US only)

$7,200+ 15% Additional Token Bonus + 2 Transferable First-Access Vouchers for a Skincare Test ($598 value, US only)

$10,400+ 15% Additional Token Bonus + 6 Transferable First-Access Vouchers for a Skincare Test ($1,794 value, US only)

*All perks will occur at the end of this offering. All token bonuses and vouchers will be issued separately by EpigenCare, not StartEngine.

Token Delivery

All tokens will be delivered by EpigenCare to your Ethereum wallet address between April 16, 2018 and June 30, 2018. If you do not possess an Ethereum wallet address, you will be provided with one along with its private access key with instructions for access and safekeeping.

The 10% Bonus for StartEngine Shareholders

EpigenCare Inc. will offer 10% additional bonus tokens for all investments that are committed by StartEngine Crowdfunding Inc. shareholders (with ≥ $1,000 invested in the StartEngine Reg A+ campaign) within 24 hours of this offering going live.

StartEngine shareholders who have invested $1,000+ in the StartEngine Reg A+ campaign will receive a 10% bonus on this offering within a 24-hour window of their campaign launch date.  This means you will receive a bonus for any tokens you purchase.  For example, if you buy 400  EPIC Tokens at $0.40 / Token, you will receive 40 EPIC Bonus Tokens bonus, meaning you'll own 440 tokens for $160.   Fractional tokens will not be distributed and token bonuses will be determined by rounding down to the nearest whole token.

This 10% Bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors receive their countersigned StartEngine Crowdfunding Inc. subscription agreement.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments. The related party, EpiGentek Group Inc., of the Company has provided a credit of line of $100,000 with 1% interest rate. As of February 15, 2018, EpiGentek has funded the Company's operating expenses in the amount of $23,032. These expenses are anticipated to be reimbursed once the Company obtains a minimum funding of $1,000,000, payable immediately (see "Use of Proceeds" section for additional information). Should the Company fail to raise this amount by December 31, 2018, the debt shall be converted to a three-year loan with the interest rate of 7%.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$0.00 USD
$0.00 USD
Cash And Cash Equivalents
$0.00 USD
$0.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
$0.00 USD
$0.00 USD


A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Less Than a Week Left to Invest + Updates

almost 2 years ago

There are only 6 days left until our equity crowdfunding (Reg CF) offering closes. This is the last chance to invest in a piece of ownership of EpigenCare before we enter subsequent private funding rounds. Some updates for everyone:

  • Development Stage: Not only do we have a functional prototype assay, but we just completed our matching algorithm that will successfully match an epigenetic skin profile to the thousands of real products and their ingredients in our prototype platform. We anticipate a fully functional closed beta version by September, followed by a mobile app version in later months.
  • Patent/IP Update: Last week we announced our filing of our US Patent application entitled "A method of creating an epigenetic skin profile associated with skin quality":
  • Beta Test Kit Waiting List: For those who wish to have first-access to our beta test kit scheduled for Y18Q4-Y19Q1 but have not pre-ordered yet, sign-up at
  • JLABS accelerator: We just moved into the JLABS accelerator space at the NY Genome Center in downtown Manhattan: We're excited to be part of a fantastic network of entrepreneurs, investors, mentors, and even customers to speed up a successful launch roadmap!
  • Mainstream Media Coverage: We've had plenty of industry love and now we're starting to see mainstream coverage. Top lifestyle sites such as Refinery29 give us confidence in our product-market fit: "It's an ambitious venture — and still in fundraising stages — but as far as truly personalized skin care goes, it's one of the most promising yet."
  • Customer Interest: Wow -- we started racking up some pre-orders before we even did any consumer facing marketing! This reinforces our product-market fit, and we will be guaranteeing these customers a slot in our Beta Test launch.

We hope you'll be part of EpigenCare's initiative to disrupt the skincare industry, bringing much needed transparency and scientific personalization to a $130 billion market!

Catch our live pitch on StartEngine Demo Day online!

almost 2 years ago

Tune in today at 12:40PM ET / 9:40 AM PT to watch EpigenCare's pitch live during StartEngine's virtual demo day -- get a chance to ask questions! Sign up here: 

Tokenizing Equity Conversion Rights for Our Investors

about 2 years ago

Additional Rights for Investors

Hi there! For those who aren't yet aware, we recently amended our securities offering. All prior existing rights remain intact, but the tokens now also include redemption rights to common stock through an equity share conversion option. Please review the Offering details again on our StartEngine page for specific information.

EpigenCare Featured on J&J Homepage

Our company is a primary focus in a featured skincare article on Johnson & Johnson's homepage. Checkout the full article at:


CEO William Lee Breaks Down EpigenCare's Business Model

In this 6 minute interview, Lee talks about EpigenCare's direct-to-consumer test, epigenetics, pricing, how it benefits both consumers and companies, and blockchain's privacy assurance feature. Agenda:

  • How does the test and platform work?
  • What is the cost and turnaround for consumers?
  • How does it benefit skincare companies?
  • What is blockchain technology and how does it solve consumer privacy concerns?

Amending our Securities Offering

about 2 years ago

Hello! Recently, a change was made to the EpigenCare offering. Here's an excerpt describing the specifics of that change:

EpigenCare has updated the terms of their offering and extended their campaign end date to 7-31-2018.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

EpigenCare Wins Johnson & Johnson Innovation's Skincare Competition

about 2 years ago

We are excited to inform you that after presenting at JLABS in San Francisco, we have been awarded as a winner in the competition! Our victory lets us walk away with $25k in prize money, accelerator space, and access to their consumer experience research initiative, mentorship, and industry network! Read the full press release here:

Also, check out our feature on J&J's website:

EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challenge

about 2 years ago

EpigenCare's personalized skincare technology and blockchain-powered digital platform has been named by Johnson & Johnson Innovation as a finalist in its Digital Beauty Quickfire Challenge. The challenge is designed to identify, recognize, and support the most innovative and future-forward digital beauty solutions. One of the key innovation areas that the challenge focuses on is personalization tools to simplify product selection and build regimen in a way that empowers consumers to make better informed skincare choices.

See full press release:

View EpigenCare's video at:

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}